Ironwood Pharmaceuticals Sector: Pharmaceuticals, with a focus on GI and rare diseases HQ: 100 Summer St, Suite 2300, Boston, MA Year Founded: 1998 Key Leaders: Thomas McCourt, CEO Number of Employees: 200300 Stage: Public Financial Snapshot: $540 million market cap Notable Investors: The Vanguard Group, BlackRock, Armistice Capital Key Products: Ironwood markets Linzess (linaclotide) for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC)
Be vigilant about watching for signs of an interaction with Ozempic
Its main role is to mediate various metabolic pathways and mainly energy production in the mitochondria of cells
There are already frameworks to support this, such as NICE [National Institute for Health and Care Excellence] guidance for pain management and prescribing e.g., NG193 and NG215. Davies added that pharmacists should support patients and prescribers to better understand these risks and help to challenge the perception that gabapentinoids are low-risk options. In January 2026, the Medicines and Healthcare products Regulatory Agency announced warnings on the risk of dependency and addiction for gabapentinoids, benzodiazepines and z-drugs are to be strengthened, following a safety review by the regulator
You'll be able to select your preferred clinic and see all available treatment options and costs before confirming your appointment
Elegantly demonstrating the causative contribution of metabolic disturbances to altered epithelial differentiation, this genetic model of primary mitochondrial dysfunction also shows a reduction in differentiated cells, including EECs, enterocytes, and tuft cells (but not enterochromaffin cells), as shown by single-cell RNA sequencing (65)